EP Patent

EP3628664A1 — Irreversible inhibitors of kras g12c mutant

Assigned to Max Planck Gesellschaft zur Foerderung der Wissenschaften eV · Expires 2020-04-01 · 6y expired

What this patent protects

The present invention relates to novel substituted 2-halopyrimidines and 5-halopyrazines, as well as pharmaceutical compositions containing at least one of these substituted 2-halopyrimidines or 5-halopyrazines together with at least one pharmaceutically acceptable carrier, excip…

USPTO Abstract

The present invention relates to novel substituted 2-halopyrimidines and 5-halopyrazines, as well as pharmaceutical compositions containing at least one of these substituted 2-halopyrimidines or 5-halopyrazines together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted 2-halopyrimidines and 5-halopyrazines are covalently binding to KRas mutant G12C and therefore, are useful for the prophylaxis and treatment of cancer by direct inhibition of the KRas G12C-oncogenic signaling in cells.

Drugs covered by this patent

Patent Metadata

Patent number
EP3628664A1
Jurisdiction
EP
Classification
—
Expires
2020-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.